Blog Posts

Three Key Actions Health + Life Science Execs Overlook During Annual Planning

Posted October 23, 2018| Fuld + Company

As Health and Life Science executives look to 2019, they should ensure their strategic and business plans thoroughly consider external risk and opportunity. In our experience, we’ve observed that companies’ planning protocols include intense scrutiny of internal considerations, but often ignore important external forces. As such, we recommend companies build planning processes that require extensive analysis of external factors that could compromise their ability to reach important goals and objectives.

The health care industry is under pressure as technological advancements and shifting public policy influence each company’s ability to competitively meet customer demand. It is resource intensive to track trends, let alone address them. Our findings echo the same sentiment. A 2018 Fuld + Company survey revealed the top strategic roadblocks in healthcare:

  • An inability to quickly respond to disruption;
  • Challenges in addressing risk factors;
  • Failing to employ competitive intelligence best practices

In our work with Health and Life Science Consulting, we have found that our clients excel at creating road-tested strategic plans when they execute three key actions:

Competition1. Thoroughly Assessing Competitor Landscape

In order to differentiate, gain market share, and develop attractive products and services, it’s critical companies understand competitors’ actions and intentions to do the same when planning processes. By shedding light on competitor strategies and best practices, executives gain an understanding of emerging rivals and new business models. As a result, executives are properly armed, as their analysis provides insights about new and existing competitors and also points to what’s likely ahead in the future.


Our additional insights in this space can be found here:


2. Evaluating Public Policy Conditions

The Affordable Care Act (ACA)’s status looms over the entire industry, with eyes on politicians and government agencies. Companies of all sizes are reinforcing their business models or creating new ones. In working with executives to help them think about the long-term and track public policy discourse, we have seen how this activity can enable more effective strategies that account for plausible policy shifts and the development of counter strategies that can be deployed quickly. As strategic planning in health and life science companies commences its critical to anticipate regulatory and policy shifts.

Our additional insights in this space can be found here:


3. Analyzing Product Lifecycle and Portfolio Strategies

Traditional planning focuses directly on product, with companies measuring the lifecycle of their product portfolio and calculating revenue flow. Gaps in planning occur when leaders only consider competitive action. Current top-line competitors may be considered, but emerging threats are often dismissed. Patent expiration is factored into the calculations, but it falls short without broad analysis pertaining to new technology that may render the patents irrelevant. During strategic planning for health and life science companies leaders must ask this key question: how do we identify and build new sources of profitable revenue, while products and services are remodeled to meet demand?

 Our  additional insights in this space can be found here:

It is only when planning is fully complemented by unbiased, externally-focused insights, that leaders can claim they are prepared to take on all that 2019 will bring.


Contact us now to explore how Fuld + Company can augment your 2019 planning and bring your executives robust analysis and insights.

Bob Flynn


As Principal Robert Flynn brings extensive international and domestic experience across business, government, and not-for-profit environments, providing strategic counsel to corporate leaders on issues relating to competitive strategy and executive decision-making.

Tags: , , ,

Related Resources

Read More

Covid-19 Impact Survey – Early Results

Intelligence professionals respond to shifts in priorities, increased pressure from management, and fewer resources. The COVID-19 induced shutdowns have reset […]

Read More

Top 4 Reasons an In-House Fuld + Company Consultant Boosts Companies’ Strategy + Intelligence Capabilities

As company-leaders plan for the year ahead, they should consider why a 3rd party on-site strategic intelligence resource might be […]

Read More

Google Health and Fake News

Being a potential major disrupter to one of the largest sectors of the economy is not smooth sailing for Google […]

Subscribe to our mailing list for our latest updates: